[1] Fang M, Zhao R, Yang Z, et al. Characterization of an anti-humanovarian carcinomaxanti-human CD3 bispecific single-chainantibody with an albumin-original interlinker[J]. Gynecol Oncol,2004, 92(1): 135-46. [2] 杨介钻, 张众, 马骊, 等. 抗人卵巢癌/抗人CD3单链双特异性抗体的生物学活性研究[J]. 癌症, 2005, 24(7): 787-91. [3] 常红, 罗微, 马骊, 等. IL-2体外诱导健康人外周血T细胞TCR β链CDR3谱系漂移的研究[J]. 南方医科大学学报, 2007, 27(4): 433-5. [4] 邹红云, 马骊, 姚新生, 等. Jurkat细胞TCR基因重排对BV CDR3的影响[J]. 南方医科大学学报, 2006, 26(7): 939-43. [5] 罗微, 马骊, 姚新生, 等. 系统性红斑狼疮患者外周血T细胞TCRβ链CDR3 谱系漂移和序列鉴定[J]. 南方医科大学学报, 2006, 26(8):1128-31. [6] Luo W, Ma L, Wen Q, et al. Analysis of the interindividualconservation of T cell receptor alpha- and beta-chain variableregions gene in the peripheral blood of patients with systemic lupuserythematosus[J]. Clin Exp Immunol, 2008, 154(3): 316-24. [7] Luo W, Ma L, Wen Q, et al. Analysis of the conservation of T cellreceptor alpha and beta chain variable regions gene in pp65peptide-specific HLA-A*0201-restricted CD8+ T cells[J]. Cell MolImmunol, 2009, 6(2): 105-10. [8] Luo W, Liao WJ, Huang YT, et al. Cancer of the gastrointestinaltract results in a restricted T-cell repertoire dependent upon tumordifferentiation[J]. Cell Immunol, 2011, 270(1): 47-52. [9] Luo W, Liao WJ, Ma L, et al. Dynamic monitoring the TCR CDR3spectratypes in patients with metastatic CRC treated with acombination of bevacizumab, irinotecan, fluorouracil, andleucovorin[J]. Cancer Immunol Immunother, 2010, 59(2): 247-56. [10]Luo W, Liao WJ, Huang YT, et al. Normalization of T cell receptorrepertoire diversity in patients with advanced colorectal cancer whoresponded to chemotherapy[J]. Cancer Sci, 2011, 102(4): 706-12. [11]Schneider MA, Brühl H, Wechselberger A, et al. In vitro and in vivoproperties of a dimeric bispecific single-chain antibody IgG-fusionprotein for depletion of CCR2 + target cells in mice[J]. Eur JImmunol, 2005, 35(3): 987-95. [12]Zocher M, Baeuerle PA. A bispecific single-chain antibody fusionprotein for targeted depletion of autoreactive B cells via unstimulatedhuman T lymphocytes[J]. Mol Immunol, 2004, 41(5): 511-8. [13]Hönemann D, Kufer P, Rimpler MM, et al. A novel recombinantbispecific single-chain antibody, bscWue-1 x CD3, inducesT-cell-mediated cytotoxicity towards human multiple myeloma cells[J]. Leukemia, 2004, 18(3): 636-44. [14]Hudson PJ, Souriau C. Engineered antibodies[J]. Nat Med, 2003, 9(1): 129-34. [15]Morecki S, Lindhofer H, Yacovlev E, et al. Induction of longlastingantitumor immunity by concomitant cell therapy withallogeneic lymphocytes and trifunctional bispecific antibody[J].Exp Hematol, 2008, 36(8): 997-1003. [16]Mølhøj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecificantibody of the BiTE class is far superior to tandem diabody withrespect to redirected tumor cell lysis[J]. Mol Immunol, 2007, 44(8):1935-43. [17]Kornacker M, Verneris M, Kornacker B, et al. The apoptotic andproliferative fate of cytokine-induced killer cells after redirection totumor cells with bispecific Ab[J]. Cytotherapy, 2006, 8(1): 13-23. [18]Viatte S, Alves PM, Romero P. Reverse immunology approach forthe identification of CD8 T-cell-defined antigens: advantages andhurdles[J]. Immunol Cell Biol, 2006, 84(3): 318-30. [19]杨介钻, 马骊, 姚新生, 等. 单链双特异性抗体(BHL-1)介导的细胞毒作用及其可能机制研究[J]. 中国免疫学杂志, 2007, 23(5): 402-6. [20]Luo W, Zhang XB, Huang YT, et al. Development of geneticallyengineered CD4+ and CD8+ T cells expressing TCRs specific for aM. tuberculosis 38-kDa antigen[J]. J Mol Med, 2011, 89(9): 903-13. |